|1.||Bian, Xiao Lu: 1 article (01/2015)|
|2.||Lai, Xue Li: 1 article (01/2015)|
|3.||Guo, Zhi Yong: 1 article (01/2015)|
|4.||Wang, Tie Yun: 1 article (01/2015)|
|5.||Gao, Xian Hua: 1 article (01/2015)|
|6.||Jia, Meng: 1 article (01/2015)|
|7.||Wang, Hai Yan: 1 article (01/2015)|
|8.||Bian, Qi: 1 article (01/2015)|
|9.||Li, Juan: 1 article (01/2015)|
|10.||Nito, Chikako: 1 article (11/2014)|
10/14/1996 - "The patient had atypical pneumonia when initially seen and his condition slowly improved with antibiotic therapy that included erythromycin lactobionate. "
04/12/1993 - "We reviewed medical records of renal transplant patients treated for pneumonia with intravenous erythromycin lactobionate. "
06/01/1983 - "A left upper lobe pneumonia developed in a patient who was receiving hemodialysis; he was treated intravenously with 1 g of erythromycin lactobionate every six hours. "
04/12/1993 - "We conclude that clinically significant hearing loss occurs in more than 30% of renal allograft recipients treated for pneumonia with intravenous erythromycin lactobionate. "
05/01/1981 - "Fever, pneumonia, and rash resolved in association with erythromycin lactobionate therapy."
10/01/1983 - "Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection."
01/01/1980 - "It is hoped that the data outlined in this paper will prove a useful baseline for future studies with erythromycin lactobionate in healthy volunteers and patients with severe infections who receive this antibiotic."
07/01/1987 - "An estimation of its concentration in uterine tissue seemed worthwhile, in order to justify the use of erythromycin lactobionate in uterine infections by sensitive micro-organisms. "
06/01/1986 - "Erythromycin lactobionate (Abbott) was administered subcutaneously 18 hours after the infection, at dosages of 270 mg/kg/day for 4 days in the animals treated with 1 LD50 and for 6 or 7 days in the animals treated with 10 LD50. "
10/01/1983 - "Sixteen patients with bronchopulmonary infection received 500 mg erythromycin lactobionate by intravenous infusion every 8 h for 2 days. "
06/01/1997 - "Erythromycin lactobionate, when administered transdermally, can be delivered at levels sufficient to treat gastroparesis. "
06/01/1997 - "Transdermal delivery of erythromycin lactobionate--implications for the therapy of gastroparesis."
01/01/1999 - "Refractory spinal cord injury induced gastroparesis: resolution with erythromycin lactobionate, a case report."
02/01/1991 - "Recent studies have shown that erythromycin lactobionate (EMLB) acts as a motilin agonist and is able to accelerate gastric emptying in diabetic gastroparesis. "
11/01/1996 - "To study the action of intravenously administered erythromycin lactobionate on human gallbladder volume, as a possible preventive method against gallbladder stone formation, in high risk patients such as those in sepsis, long standing fasting periods or those receiving prolonged total parenteral nutrition or octreotide. "
|7.||Messenger RNA (mRNA)
|3.||Total Parenteral Nutrition